P3373Better health-related quality of life in patients treated with sacubitril/valsartan compared with enalapril, irrespective of NYHA class: Analysis of EQ-5D in PARADIGM-HF

Trueman, David; Kapetanakis, Venediktos; Briggs, Andrew; Lewis, Eldrin F.; Rouleau, Jean L.; Solomon, Scott D.; Swedberg, Karl; Zile, Michael R.; Packer, Milton; McMurray, John J.V.; Croft, D.; Haroun, R; Gielen, V

doi:10.1093/eurheartj/ehx504.p3373

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 For the QALY calculations, EQ-5D utility values from PARADIGM-HF were used, since no German-specific utilities were found in the literature. 50,51 The baseline utility value was 0.78, a disutility value of 0.21 was used for hospitalized patients and for sacubitril/valsartan treatment a utility benefit of 0.011 was incorporated. 50,51 Time horizon and discounting A 30-year time horizon was used to approach a lifetime horizon, with a starting age of 64.…”

Section: Health Outcomes and Utilitiesmentioning

confidence: 99%

“…50,51 The baseline utility value was 0.78, a disutility value of 0.21 was used for hospitalized patients and for sacubitril/valsartan treatment a utility benefit of 0.011 was incorporated. 50,51 Time horizon and discounting A 30-year time horizon was used to approach a lifetime horizon, with a starting age of 64. Both costs and effects were discounted at 3%, with 0% and 5% used in scenarios, in line with the German guidelines.…”

Section: Health Outcomes and Utilitiesmentioning

confidence: 99%

See 1 more Smart Citation

Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier

et al. 2019

View full text Add to dashboard Cite

Using the German HTA guidelines, the ICER is not taken into consideration. Instead, the efficiency frontier was introduced as an alternative, to avoid the use of QALYs and the setting of willingness-to-pay thresholds. • We conducted the first direct comparison of the German efficiency frontier methodology to the conventional ICER, using sacubitril/valsartan, a new treatment for patients with chronic heart failure with a reduced ejection fraction. • Sacubitril/valsartan has a favourable ICER in the German setting, comparable to other European countries. However, using the efficiency frontier, the results would inform decision makers that a considerable discount needs to be negotiated.

show abstract

Section: Health Outcomes and Utilitiesmentioning

confidence: 99%

Section: Health Outcomes and Utilitiesmentioning

confidence: 99%

Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A review of data by NYHA class clearly illustrates the impact of the severity of chronic HF on utility values. The SLR identified 11 publications that provided data on mean EQ-5D utility values according to NYHA class, of which nine were included in the IQL calculation; one study was omitted from the IQL calculation as it grouped NYHA classes (I/II and III/IV), and a second study was omitted because it published the mean difference in utility values between classes [33,34]. Aside from Zhu et al [30], which reported lower utility values for NYHA I vs NYHA class II, increasing NYHA class was associated with lower utility values ( The impact of a value set on the utility value is illustrated in two publications.…”

Section: Utility Values In Patients With Chronic Hfmentioning

confidence: 99%

Health State Utilities of Patients with Heart Failure: A Systematic Literature Review

et al. 2020

View full text Add to dashboard Cite

Background and Objectives New treatments and interventions are in development to address clinical needs in heart failure. To support decision making on reimbursement, cost-effectiveness analyses are frequently required. A systematic literature review was conducted to identify and summarize heart failure utility values for use in economic evaluations. Methods Databases were searched for articles published until June 2019 that reported health utility values for patients with heart failure. Publications were reviewed with specific attention to study design; reported values were categorized according to the health states, 'chronic heart failure', 'hospitalized', and 'other acute heart failure'. Interquartile limits (25th percentile 'Q1', 75th percentile 'Q3') were calculated for health states and heart failure subgroups where there were sufficient data. Results The systematic literature review identified 161 publications based on data from 142 studies. Utility values for chronic heart failure were reported by 128 publications; 39 publications published values for hospitalized and three for other acute heart failure. There was substantial heterogeneity in the specifics of the study populations, methods of elicitation, and summary statistics, which is reflected in the wide range of utility values reported. EQ-5D was the most used instrument; the interquartile limit for mean EQ-5D values for chronic heart failure was 0.64-0.72. Conclusions There is a wealth of published utility values for heart failure to support economic evaluations. Data are heterogenous owing to specificities of the study population and methodology of utility value elicitation and analysis. Choice of value(s) to support economic models must be carefully justified to ensure a robust economic analysis.

show abstract

P3373Better health-related quality of life in patients treated with sacubitril/valsartan compared with enalapril, irrespective of NYHA class: Analysis of EQ-5D in PARADIGM-HF

Cited by 2 publications

References 0 publications

Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier

Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier

Health State Utilities of Patients with Heart Failure: A Systematic Literature Review

Contact Info

Product

Resources

About